#United States #Anixa Biosciences #San Jose #CAR-T therapy #Ovarian Cancer

Anixa Biosciences Unveils CAR-T Therapy for Ovarian Cancer

Anixa Biosciences, a leader in biotechnology specializing in cancer treatments, recently announced an important milestone for its CAR-T therapy targeting ovarian cancer. This breakthrough will be highlighted at the International Society for Cell & Gene Therapy (ISCT) 2026 Annual Meeting, to be held from May 6 to 9 in Dublin, Ireland.

The presentation will be delivered by Cheryl Cox, the Operations Director at the Cell Therapies and Gene Expression Engineering Facility at Moffitt Cancer Center. She will discuss the pivotal clinical trial design of Anixa’s immunotherapy, known as lira-cel, which employs a unique approach to harness the body’s immune system against ovarian cancer's recurrence. Specifically, this treatment is engineered to target the follicle-stimulating hormone receptor (FSHR), which is not only expressed on ovarian tumor cells but also on surrounding tumor vasculature, presenting a selective attack on malignant cells while sparing healthy tissue.

Understanding CAR-T Therapy

CAR-T therapy has emerged as a revolutionary approach in cancer treatment, employing genetically modified T cells to enhance anti-tumor responses. Lira-cel represents a significant innovation as it utilizes chimeric endocrine receptor-T cell (CER-T) technology, differing from traditional methods where an antibody fragment binds to tumor cells. Instead, lira-cel harnesses the natural ligand of the FSHR receptor, FSH, maximizing targeting efficiency.

The ongoing Phase 1 clinical trial, identified as ClinicalTrials.gov NCT05316129, is currently enrolling adult women who have recurrent ovarian cancer and have undergone at least two prior therapies. This trial assesses the safety and efficacy of lira-cel in halting tumor progression, offering hope to a patient population that has limited treatment options.

The ISCT Annual Meeting: A Hub for Innovation

The ISCT 2026 Annual Meeting promises to be a gathering point for more than just Anixa’s presentation. With thousands of experts expected to attend, the event will showcase hundreds of talks, presentations, and workshops focused on translating advanced cellular therapies into clinical practice. Topics will cover cutting-edge advancements in gene editing and bioprocessing, along with providing professionals ample opportunities to network and forge collaborations.

Anixa Biosciences stands at the forefront of cancer treatment, utilizing its partnerships with esteemed research institutions like Moffitt Cancer Center and Cleveland Clinic. The company’s strategic collaboration aims to pioneer next-generation therapies against various cancers, including breast and ovarian cancer vaccines, which are engineered to activate the immune system against tumor-associated proteins.

What Lies Ahead

As the ISCT 2026 approaches, anticipation grows around the developments in cell and gene therapies. Anixa's commitment to advancing innovative treatments is evident, aiming to make a significant impact in cancer therapy. The results from the ongoing clinical trials, particularly lira-cel’s efficacy, could potentially shift paradigms in the management of ovarian cancer, offering hope to many affected individuals.

To learn more about Anixa Biosciences and its groundbreaking work in the field of cancer therapy, visit their official website or their social media channels on LinkedIn, X, Facebook, and YouTube for more updates leading up to the conference and beyond.